Key points from article :
Co-led by Mubadala Capital and Horizons Ventures, funding will power Juvena’s AI-enabled drug discovery platform to map the therapeutic potential of secreted proteins.
Juvena Therapeutics announced that it has raised $41 million in Series A, bringing its total funding to $50 million.
It will advance the company’s biologics pipeline targeting chronic and age-related diseases.
Secreted proteins are a proven class of biologics with tremendous therapeutic potential.
They regulate tissue repair and regeneration, organ development, and immune response to disease.
To systematically uncover the therapeutic links between secreted proteins and diseases, Juvena has developed a computational platform.
It combines a compounding database mapping secreted proteins to specific diseases.
“We are thrilled to scale our platform ... and chronic, debilitating diseases,” said Hanadie Yousef, Co-founder and Chief Executive Officer of Juvena.